Analysts Offer Insights on Healthcare Companies: Alimera (NASDAQ: ALIM), MacroGenics (NASDAQ: MGNX) and Chimerix (NASDAQ: CMRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alimera (NASDAQ: ALIM), MacroGenics (NASDAQ: MGNX) and Chimerix (NASDAQ: CMRX) with bullish sentiments.

Alimera (NASDAQ: ALIM)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Alimera (NASDAQ: ALIM), with a price target of $2.50. The company’s shares closed yesterday at $1.04, close to its 52-week low of $1.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.8% and a 37.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.

See today’s analyst top recommended stocks >>

MacroGenics (NASDAQ: MGNX)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on MacroGenics (NASDAQ: MGNX), with a price target of $34. The company’s shares closed yesterday at $22.50.

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.1% and a 47.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.

MacroGenics has an analyst consensus of Strong Buy, with a price target consensus of $31.67.

Chimerix (NASDAQ: CMRX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Chimerix (NASDAQ: CMRX), with a price target of $10. The company’s shares closed yesterday at $4.77.

According to TipRanks.com, White is a 5-star analyst with an average return of 24.8% and a 53.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Mirati Therapeutics.

Chimerix has an analyst consensus of Hold, with a price target consensus of $8.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.